Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results
Phase III Data Could Lead To First Approval
Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.